Medical Spas Are Still Selling Compounded Weight-Loss Drugs — And a New Study Says That's a Problem
A University of Colorado Anschutz study finds some med spas still dispensing compounded GLP-1s from pharmacies with regulatory red flags.
Excellent. I now have strong sourcing. Let me write the article.
Medical Spas Are Still Selling Compounded Weight-Loss Drugs — And a New Study Says That's a Problem
The FDA declared the shortage of semaglutide officially over. Compounding pharmacies were supposed to stop making knock-off versions. And yet, walk into certain medical spas across the country right now and you can still get a vial of compounded GLP-1 drug — no questions asked, no specialist in sight.
A new study out of the University of Colorado Anschutz, published July 17, 2026, found that some medical spas are continuing to sell compounded weight-loss injectables sourced from pharmacies flagged with regulatory concerns. That's not a gray area. That's a red flag — and it's worth understanding exactly what it means for anyone navigating this space.
What "Compounded" Actually Means
Compounded drugs are custom-made versions of medications, typically mixed by a pharmacy rather than manufactured by a brand-name drug company. They've long served a legitimate purpose — for patients with allergies to standard ingredients, or when a commercially available drug is genuinely in shortage.
The key word is genuinely. The FDA permits compounding of specific drugs under shortage conditions, governed by rules for so-called 503A and 503B pharmacies. 503A pharmacies compound for individual patient prescriptions; 503B "outsourcing facilities" can produce larger batches but face stricter federal oversight.
When the FDA removed semaglutide from its drug shortage list — a move that Pharmacy Times reported in May 2026 as part of a push to "permanently close the door on compounded GLP-1s" — the legal rationale for most compounding evaporated. Pharmacies that kept producing it anyway moved into legally dubious territory.
The Safety Signal You Need to Know About
This isn't just a paperwork problem. There's a real pharmacovigilance signal attached to compounded GLP-1 drugs.
A March 2026 study published in Expert Opinion on Drug Safety analyzed FDA adverse event reports tied to compounded GLP-1 receptor agonists. According to the PubMed-indexed study by McCall et al., the FDA's adverse event reporting system captured a meaningful safety profile for compounded versions — separate from the data on FDA-approved drugs like Wegovy or Ozempic.
To be clear: adverse event reports are reports, not confirmed causal links. But they matter. When a drug is made in a compounding pharmacy rather than a regulated manufacturing facility, there's no guarantee of sterility, concentration accuracy, or ingredient purity. A vial labeled "semaglutide 1 mg" from an unverified source may contain more, less, or something entirely different.
The FDA's approved Wegovy label already carries serious warnings — including risks of acute pancreatitis, gallbladder disease, kidney injury from dehydration, and hypersensitivity reactions — and that's for the rigorously manufactured, dose-verified brand-name product. The risk calculus shifts when manufacturing controls are unknown.
Why Medical Spas Are a Particular Concern
Medical spas occupy a strange middle ground in healthcare. They're not hospitals, not traditional clinics, and oversight varies dramatically by state. Some operate under the supervision of a licensed physician. Others are run by aestheticians or nurse practitioners working under arrangements that may not include robust prescriber oversight.
That's the context that makes the University of Colorado Anschutz findings so pointed. It's not just that compounded drugs are being sold — it's where and how. A February 2026 report from the Indiana Capital Chronicle noted that Indiana lawmakers heard warnings specifically about medical spas and compounded drugs — a sign that state-level concern has been building for months.
Meanwhile, the FDA's own enforcement escalation has been well-documented. EMJ reported in June 2026 that the agency has stepped up its crackdown on compounded GLP-1 production — and the DOJ has been looped in on referrals, according to a February 2026 legal analysis from Buchanan Ingersoll & Rooney. A physician was even sentenced to probation in April 2026 for illegally importing weight-loss drugs, according to the Partnership for Safe Medicines. The enforcement environment is clearly tightening — but the University of Colorado study suggests the market hasn't fully responded.
What This Means for You
If you're using or considering GLP-1 medications, here's what to take from this:
- Ask where your drug comes from. If you're getting a weight-loss injectable from a med spa, ask directly: Is this FDA-approved (Wegovy, Zepbound, Ozempic, Mounjaro)? Or is it compounded? If compounded, which pharmacy made it, and is that pharmacy on FDA's 503B registered outsourcing facility list?
- A lower price tag is not automatically a deal. Compounded versions may cost less, but if the source pharmacy has regulatory flags, you have no reliable way to know what's actually in the vial.
- Your prescriber matters. MedlinePlus notes that obesity is a complex disease — and the drugs used to treat it carry real risks even when manufactured correctly. A med spa selling injectables without robust medical oversight is not the same as a prescriber-supervised weight management program.
Not medical advice. Talk to your prescriber about your specific situation, medications, and treatment options.
